EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study

Yu Yan iD, Xiaoyan Liu iD, Yang Du iD, Qiqi Dou iD, Hanping Wang iD, Xiaoyan Si iD, Xiaotong Zhang, Xuefei Wu iD, Yunzhi Zhou, Mei Li, Wei Zhong iD, Mengzhao Wang iD und 1 weitere

The Oncologist · 06.06.2026 · 31 (7)

DOI: 10.1093/oncolo/oyag192 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 20.05.2026. Verfasst von Yu Yan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medic…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoplasms, Fever. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bethune Charitable Foundation Advanced Solid Tumor Research Funding, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoplastic fever (NF) severely impairs quality of life and often limits antitumor therapy, yet effective treatment remains lacking. Given the central role of interleukin-6 (IL-6), we evaluated tocilizumab for NF management.

Methods

We retrospectively reviewed NF cases at 3 Chinese hospitals (2019-2023). Patients who received tocilizumab and had evaluable follow-up data were included in analyses of fever resolution, afebrile duration, Karnofsky Performance Status, inflammatory markers, antitumor outcomes, and adverse events (AEs). In patients with sequential exposure to non-steroidal anti-inflammatory drugs (NSAIDs) and tocilizumab, changes in inflammatory markers after each treatment were compared.

Results

Forty-five patients were identified (median age 65). All had elevated CRP and IL-6. Among 22 treated with tocilizumab, all achieved fever resolution within 24 hours, sustained for ≥2 weeks, with significant reductions in CRP (mean, 95.7-19.0 mg/L) and other inflammatory markers. Median afebrile duration was 3 weeks, extended to 4 weeks with re-treatment. Systemic therapy was subsequently administered in patients with poor baseline performance, who achieved an objective response rate of 50%, a median progression-free survival of 11.6 months, and an overall survival of 21.3 months. AEs occurred in 81.8% (grade ≥3, 31.8%) but were manageable. Compared with NSAIDs, tocilizumab uniquely improved anemia and inflammatory control.

Conclusion

Tocilizumab provided rapid and durable fever resolution with systemic anti-inflammatory effects, accompanied by functional and hematologic improvement. These findings suggest IL-6 blockade as a promising therapeutic option for NF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNeoplasmsFeverHumansFemaleMaleRetrospective StudiesAgedMiddle AgedInterleukin-6AdultAged, 80 and over

Stichwörter der Autor:innen

interleukin-6neoplastic feversolid tumorssupportive caretocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedInterleukin-6

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
  • Liaoning University of Traditional Chinese Medicine Xinglin College, Shengyang, 110135, China.
  • Department of Medicine, Beijing Water Conservancy Hospital, Beijing, 100036, China.
  • Department of Respiratory Medicine, Emergency General Hospital, Beijing, 100028, China.

ORCID-Profile: Yu Yan, Xiaoyan Liu, Yang Du, Qiqi Dou, Hanping Wang, Xiaoyan Si, Xuefei Wu, Wei Zhong, Mengzhao Wang, Li Zhang

Förderung

  • Bethune Charitable Foundation Advanced Solid Tumor Research Funding
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Yan, Y., Liu, X., Du, Y., Dou, Q., Wang, H., Si, X., Zhang, X., Wu, X., Zhou, Y., Li, M., Zhong, W., Wang, M., & Zhang, L. (2026). Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag192

Vancouver

Yan Y, Liu X, Du Y, Dou Q, Wang H, Si X, et al. Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag192

BibTeX
@article{Yan2026,
  author = {Yan, Yu and Liu, Xiaoyan and Du, Yang and Dou, Qiqi and Wang, Hanping and Si, Xiaoyan and Zhang, Xiaotong and Wu, Xuefei and Zhou, Yunzhi and Li, Mei and Zhong, Wei and Wang, Mengzhao and Zhang, Li},
  title = {Efficacy and safety of tocilizumab for neoplastic fever in patients with advanced solid tumors: a multicenter retrospective study},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {7},
  doi = {10.1093/oncolo/oyag192}
}
Kostenlos starten →